Skip to main content
. 2017 Sep 21;39(2):205–212. doi: 10.1038/aps.2017.85

Table 3. 12-Month clinical outcomes.

  Cilostazol (n=205) Aspirin (n=408) P value OR 95% CI
MACE [n (%)] 10 (4.9%) 34 (8.3%) 0.118 0.56 0.27–1.17
Cardiac death 2 (0.98%) 3 (0.74%) 0.755 1.33 0.22–7.81
Restenosis 3 (1.5%) 20 (4.9%) 0.035 0.29 0.09–0.98
Myocardial infarction 4 (1.9%) 14 (3.4%) 0.306 0.56 0.18–1.72
Stroke [n (%)] 1 (0.49%) 0 0.158 -- --
TVR 5 (2.4%) 15 (3.7%) 0.416 0.65 0.23–1.83
Bleeding 1 (0.49%) 11 (2.7%) 0.063 0.18 0.02–1.38